Updated project metadata. NHCF-V primary cardiac fibroblasts where treated for 24 hours with either 1) 100nM Halofuginone (TMT labels 126 and 129L) 2) 300nM Halofuginone (TMT labels 127L and 129H) 3) 300 nM Halofuginone + 4 mM L-Pro (TMT labels 127H and 130L) 4) DMSO (TMT labels 128H and 131)